Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer
June 4th 2022Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.
The Saga of Regional Therapy in the Treatment of Ovarian Cancer
May 17th 2022Despite numerous well-designed and conducted randomized trials, a definitive answer to the role of specific disease management remains unclear, particularly in the discussions of the optimal role for the regional delivery of cytotoxic chemotherapy in the treatment of patients with ovarian cancer.
Pal Discusses Eye-Catching ASCO GU Data in RCC
May 16th 2022Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.
Emerging Targeted Therapies Continue to Shift Paradigm in EGFR Exon 20–Mutated NSCLC
Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.
Cancer Treatment Centers of America Grows Medical Oncologist Roster Across Hospitals
April 1st 2022Medical oncologists Dr. Ajaz Khan, Dr. Ryan Engel, and Dr. Nitika Sharma are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America®.
Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022
March 24th 2022Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.
Regorafenib/Pembrolizumab Misses PFS End Point in MSS CRC, But Biomarker Analyses Are Ongoing
Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.
Earlier Introduction of ADCs, PARP and CDK4/6 Inhibitors Improve Outcomes in Breast Cancer
February 13th 2022Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.